Home - Products - Angiogenesis - HER/HSP - BMS 599626 2HCl (873837-23-1(HCl))

BMS 599626 2HCl (873837-23-1(HCl))

CAS No. 1781932-33-9

BMS 599626 2HCl (873837-23-1(HCl))( —— )

Catalog No. M35292 CAS No. 1781932-33-9

BMS 599626 2HCl (873837-23-1(HCl)) (AC480 dihydrochloride) is a selective inhibitor of HER1 and HER2 (IC50s: 20 nM and 30 nM), ~8-fold less potent to HER4, >100-fold to Lck, VEGFR2, c-Kit, MET, etc.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 76 Get Quote
5MG 107 Get Quote
10MG 169 Get Quote
25MG 347 Get Quote
50MG 513 Get Quote
100MG 709 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    BMS 599626 2HCl (873837-23-1(HCl))
  • Note
    Research use only, not for human use.
  • Brief Description
    BMS 599626 2HCl (873837-23-1(HCl)) (AC480 dihydrochloride) is a selective inhibitor of HER1 and HER2 (IC50s: 20 nM and 30 nM), ~8-fold less potent to HER4, >100-fold to Lck, VEGFR2, c-Kit, MET, etc.
  • Description
    BMS 599626 2HCl (873837-23-1(HCl)) (AC480 dihydrochloride) is a selective inhibitor of HER1 and HER2 (IC50s: 20 nM and 30 nM), ~8-fold less potent to HER4, >100-fold to Lck, VEGFR2, c-Kit, MET, etc.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    HER/HSP
  • Recptor
    HER
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1781932-33-9
  • Formula Weight
    603.48
  • Molecular Formula
    C27H29FN8O3Cl2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(OC[C@@H]1COCCN1)NC2=CN3C(C(NC4=CC=C(N(N=C5)CC6=CC(F)=CC=C6)C5=C4)=NC=N3)=C2C.Cl.Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Trastuzumab

    Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.

  • Zongertinib

    Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (TKD).

  • BENZYLACETONE

    Used in soap perfumes.